Syndrome of inappropriate antidiuretic hormone classification

Syndrome of inappropriate antidiuretic hormone Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differential Diagnosis
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Syndrome of inappropriate antidiuretic hormone classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Syndrome of inappropriate antidiuretic hormone classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Syndrome of inappropriate antidiuretic hormone classification
CDC on Syndrome of inappropriate antidiuretic hormone classification
Syndrome of inappropriate antidiuretic hormone classification in the news
Blogs on Syndrome of inappropriate antidiuretic hormone classification
Directions to Hospitals Treating Syndrome of inappropriate antidiuretic hormone
Risk calculators and risk factors for Syndrome of inappropriate antidiuretic hormone classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]

Overview

SIADH may be classified into several sub-types based on the pattern of AVP( arginine vasopressin) secretions across a range of plasma osmolalities: Type A, type B, type C, type D.

Classification

SIADH may be classified in to several sub-types based on the pattern of AVP secretion across a range of plasma osmolalities:

Classification	Features
TypeA	The commonest form of SIADH responsible for a much higher proportion of SIADH, at around 60–70%. Exhibit excessive, random secretion of AVP, with loss of the close linear relationship between plasma osmolality and plasmaAVP. Common in lung cancer Invitro studies have demonstrated that some lung tumours synthesize AVP, and that tumour tissue stains positive for AVPmRNA Plasma AVP concentrations in type A SIADH are not suppressed physiologically by drinking , which makes patients vulnerable to the development of severe hyponatremia. Studies have also demonstrated a lowerosmotic threshold for thirst appreciation in this type of SIADH. This type of SIADH is also characteristic of nasopharyngeal tumours, which also stain positive for AVP mRNA
Type B	Accounts for (20–40%) of the cases The osmoticthreshold for AVP release is lowered – a reset osmostat – such that secretion of AVP occurs at lower plasma osmolalities than normal. *Because AVP is suppressed at plasma osmolalities below the lower, reset threshold, further over-hydration leads to suppression of AVP release, which protects against the progression to severehyponatraemia. Although most tumours manifest type ASIADH, some also present with type B SIADH, so thepattern of abnormalAVP (arginine vasopressin) secretion cannot be utilized to predict the causation of SIADH.
TypeC	A rare condition characterized by failure to suppress AVP secretion at plasma osmolalities below the osmotic threshold. Plasma AVP concentrations are thus inappropriately high at low plasma osmolalities, but there is a normal relationship between plasma osmolality and plasma AVP at physiological plasma osmolalities. This variant may be due to dysfunction of inhibitory neurons in the hypothalamus, leading to persistent low-grade basal AVP secretion.
Type D	Type D: Is a rare clinical picture of SIADH with low or undetectableAVPevels and no detectable abnormality in circulating AVP response . It is thought that a nephrogenic SIADH (NSIAD) may be responsible for this picture . Gain-of-function mutations in the V2 receptor leading to a clinical picture of SIADH, with undetectable AVP levels, have been described. The identified mutations had different nucleotide substitutions causing different levels of V2 receptor activation. This syndrome appears to be inherited in an X-linked manner,although heterozygous females may have varying degrees of inappropriate antidiuresis. Owing to variable expressivity of the gene involved, NSIAD may be clinically undetectable for years, until other contributing factors in later life lead to clinically significant hyponatraemia .